ACHE and Alzheimer disease: These dual-binding site ligands would have greater AChE inhibitory potency due to their greater affinity and consequently greater efficacy for the symptomatic treatment of AD, and furthermore they would be expected to additionally exhibit neuroprotective effects arising from the inhibition of the AChE-induced Aβ aggregation [28,29,30].